Genmab A/S (NASDAQ:GMAB) Stake Lifted by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. lifted its position in Genmab A/S (NASDAQ:GMAB) by 11.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 70,632 shares of the company’s stock after acquiring an additional 7,242 shares during the period. Crossmark Global Holdings Inc.’s holdings in Genmab A/S were worth $1,775,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. International Assets Investment Management LLC bought a new stake in Genmab A/S during the fourth quarter worth about $393,000. Benjamin F. Edwards & Company Inc. acquired a new position in Genmab A/S in the 4th quarter valued at about $216,000. M&T Bank Corp raised its holdings in Genmab A/S by 87.8% in the 4th quarter. M&T Bank Corp now owns 15,432 shares of the company’s stock valued at $492,000 after acquiring an additional 7,213 shares in the last quarter. Vestmark Advisory Solutions Inc. grew its holdings in shares of Genmab A/S by 28.5% during the 4th quarter. Vestmark Advisory Solutions Inc. now owns 35,656 shares of the company’s stock valued at $1,135,000 after purchasing an additional 7,905 shares during the last quarter. Finally, Principal Securities Inc. acquired a new position in Genmab A/S during the 4th quarter worth about $77,000. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Performance

GMAB traded down $0.01 during trading on Friday, reaching $27.80. The company’s stock had a trading volume of 347,183 shares, compared to its average volume of 581,380. The company has a market capitalization of $18.38 billion, a price-to-earnings ratio of 23.13, a price-to-earnings-growth ratio of 1.01 and a beta of 0.97. Genmab A/S has a 52-week low of $24.53 and a 52-week high of $39.53. The company’s fifty day moving average price is $26.82 and its 200-day moving average price is $28.15.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). Genmab A/S had a return on equity of 18.90% and a net margin of 30.74%. The firm had revenue of $779.50 million for the quarter, compared to analyst estimates of $734.60 million. Equities analysts predict that Genmab A/S will post 1.13 earnings per share for the current year.

Wall Street Analyst Weigh In

GMAB has been the topic of a number of recent research reports. Truist Financial raised their target price on Genmab A/S from $50.00 to $53.00 and gave the company a “buy” rating in a report on Tuesday, June 4th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Genmab A/S in a report on Tuesday, August 20th. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Tuesday. Royal Bank of Canada upgraded shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a report on Monday, July 15th. Finally, BTIG Research boosted their price target on Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Three analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $49.50.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.